Feedback / Questions
mipasetamab uzoptirine (ADCT-601) - Overland ADCT BioPharma
camidanlumab tesirine (ADCT-301) - Genmab, ADC Therapeutics
epratuzumab-cys-tesirine (ADCT-602) - Overland ADCT BioPharma
ADCT-901 - Overland ADCT BioPharma
https://www.globenewswire.com/news-release/2023/08/08/2720412/0/en/ADC-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html
Aug 8, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next